cyrilzakka/clinical-trials huggingface dataset:
Comparison of Quadratus Lumborum Intramuscular and Transmuscular in Postoperative Pain

Acute pain is reported in approximately 80% of patients undergoing postoperative care for various types of surgical procedures in the United States. Another study reported patient postoperative pain intensity with 75% with severe pain in the first 1 to 2 postoperative days and 38% reporting moderate to severe pain at 14 postoperative days. Several modalities have been used as the standard for the management of pain postoperative C-sections.

One of the postoperative analgesic modalities for SC is quadratus lumborum block (QLB). This technique has advantages in relieving postoperative pain after C-section because it is considered to be able to relieve visceral pain as well as somatic pain. The transmuscular QLB (QLBT) approach is one of the most frequently used. This technique was found to be effective with regard to the distribution of analgesics to the paravertebral spaces which is the hallmark of QLB. However, this technique was found to be difficult to perform. Difficulties were reported related to the position of the procedure i.e. lateral or sitting position.


Eligibility Criteria:
Inclusion Criteria:

* Underwent C-section with subarachnoid block
* Aged 18-35 years old.
* ASA preoperative physical status 1-2

Exclusion Criteria:

* Coagulopathy
* Anatomic abnormalities of the abdomen
* History of allergy to local anesthesia
* History of hyperalgesia
* History of drug abuse (sedatives, opioids, paracetamol, or other pain relievers)
* Require postoperative intensive care
* Refuse to participate in research.
Safety Study of Pneumococcal 13-valent Conjugate Vaccine in Healthy People Aged 2 Months and Older

This study evaluates the safety of Pneumococcal 13-valent Conjugate Vaccine in Healthy People Aged 2 Months and Older.120 Subjects will be equally divided into 4 groups,including 18 years and older,2-5 years old, 2 months old and 3 months old. Subjects aged 18 years and 2-5 years old will receive one dose of PCV13 vaccine,while subjects aged 2 and 3 months will receive 3 doses of PCV13 vaccine,injected at 2, 4, 6 months or 3、4、5 months respectively.


Eligibility Criteria:
Inclusion Criteria:

1. Healthy babies with health conditions confirmed according to medical history, medical examination and judgment of researchers;
2. Satisfy the age requirements of the clinical trial.(children from 2 months to 5 years old and adults over the age of 18);
3. Parents or guardians of the subjects must provide informed consent forms with personally signature and date;
4. Parents or guardians of the subjects have been informed of all aspects of the research;
5. Subjects or guardians can obey the requirements of the clinical research;
6. No pneumococcal vaccine inoculation history, no other preventive vaccination within 7 days;
7. Axillary temperature below 37℃

Exclusion Criteria:

1. People with pneumococcal vaccine inoculation history, no matter experimentally or already on the market;
2. People has allergic reaction to any drugs, vaccine or vaccine-related components previously;
3. People has allergic reaction to 13vPnC, 7vPnC or other complexes associated with the drug, known or suspected;
4. People has hemorrhagic physical constitution or diseases that prolong bleeding time, intramuscular injection taboo;
5. People has immune deficiency or immune function inhibition, known or suspected;
6. People has irritability, convulsions, epilepsy, brain diseases and mental history or family history;
7. People has culture-confirmed invasive diseases caused by streptococcus pneumoniae history;
8. People has serious congenital malformations or serious chronic diseases that are known, people with congenital deformities, stunted or has a clinical diagnosis of serious chronic diseases (such as Down syndrome, diabetes, sickle cell anemia or nerve disorders, Guillain-Barre syndrome);
9. People suffers from these diseases: respiratory diseases, acute or chronic active stage of infection, severe cardiovascular disease, kidney and liver diseases, malignant tumors, skin diseases, babies with HIV infected mothers(inspection report is available);
10. People with vaccination-related contraindications that other researchers believe;
11. People take part in other clinical trials while taking part in this clinical trial or 28 days before this clinical trial. People who participate in purely observational studies are acceptable;
12. People received blood products or intravenous immunoglobulin. People who was inoculated Hepatitis B immunoglobulin can be acceptable.
The Comparison of Hypotension Incidence Between Remimazolam and Propofol in Hypertensive Patients Undergoing Neurosurgery

This study aims to find an excellent drug in terms of hemodynamic stability when comparing the propofol and remifentanil with the combined use of remimazolam and remifentanil. When the mean blood pressure falls by 20% or more from the baseline mean blood pressure, it is considered hypotension, and a vasopressor such as ephedrine, phenylephrine, or norpin is used to control the blood pressure to within 20% of the baseline blood pressure. If the blood pressure increases by 20% or more above the baseline mean blood pressure, nicardipine infusion or remimazolam, propofol or remifentanil should be increased to control the blood pressure.


Eligibility Criteria:
Inclusion Criteria:

1. hypertension
2. patients undergoing neurosurgery
3. ASA I-III
4. 19-75 year-old patients

Exclusion Criteria:

1. emergency
2. Patients admitted on the day of surgery
3. cardiac disease
4. liver failure or liver cirrhosis
5. increased intracranial pressure(IICP)
6. mental change
7. Foreigner
8. iliteracy
Skin Hydration in Persons With Acne After Dietary Supplementation With Botanical Antioxidants

Antioxidants have been studied for their abilities to combat reactive oxygen species in a multitude of conditions. This study aims to assess whether the botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB), taken orally daily for 8 weeks, can assist with Acne vulgaris as well as skin hydration and quality of life for those with acne.

The study will be a 2-armed investigational trial with one group receiving botanical dietary supplement and one placebo group provided with the similar supplement vehicle. The trial will be double-blind, randomized, parallel-group study. The investigational group will receive the botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB), to be taken orally daily for 8 weeks. Control group participants will receive the HBKB botanical dietary supplement vehicle as a placebo to be taken orally daily for 8 weeks.Participants will have their skin assessed

Eligibility Criteria:
Inclusion Criteria:

* Adults 18-35 years of age able to provide consent to participate
* IGA of mild to moderately severe facial Acne Vulgaris (AV) at screening
* Potential participants with mild to moderately severe facial AV and with AV on their neck, shoulders, chest and/or back body surface areas may be included.

Exclusion Criteria:

* An Investigator Global Assessment IGA of severe facial, neck, back or truncal AV
* Diagnosis of a chronic inflammatory disease such as lupus, multiple sclerosis, cancer, Chron's disease or cancer
* Allergies to Astaxanthin (microalgae), Grape Seed Extract, Kiwi fruit or Kiwi extract, Pineapple fruit or extract (bromelain), Rosehip or Rosehip extract, Gooseberry, Rosehip, Grapes
* Secondary AV, such as occupational AV, steroid induced AV, or AV associated with endocrine disorders
* Having facial dermatosis that may interfere evaluations by IGA such as sunburn, eczema, psoriasis, erythematotelangectatic rosacea or seborrheic dermatitis
* Use of isotretinoin within 2 months
* Use of adapalene or tretinoin within 2 weeks
* Use of anti-biotics within 2 weeks
* Use of oral corticosteroids or androgens within 2 weeks
* Use of anticonvulsants
* Any subject who the PI deems unsuitable for any reason
The Reliability and Validity of Turkish Version of ''The Dyspnea-ALS-Scale (DALS-15)"

The Dyspnea-ALS-Scale (DALS-15) is a uni-dimensional scale to measure dyspnea in patients with Amyotrophic Lateral Sclerosis. It can be easily and rapidly applied. The aim of this study is to investigate reliability and validity of Turkish version of the DALS-15.


Eligibility Criteria:
Inclusion Criteria:

* Age of 18 or above
* Dyspnea on exertion, dyspnea at rest, or orthopnea without evidence of pulmonary or cardiac causes of dyspnea

Exclusion Criteria:

* Severe cognitive dysfunction
Treatment Resistant Depression and Insomnia in Older Veterans

The purpose of this pilot study is to obtain information about older Veterans' preferences for treatment of depression and insomnia and to pilot test the feasibility and clinical effect of Brief Behavioral Treatment for Insomnia (BBTI) BBTI for older Veterans living with Treatment Resistant Depression (TRD) and insomnia.

Quantitative and qualitative methods will be used to obtain information to aid in developing treatment approaches appropriate for older Veterans with TRD and insomnia. Qualitative data will be gathered to better understand Veterans' preferences for treatment approaches, particularly relating to preference for pharmacotherapy versus augmentation with a behavioral intervention such as BBTI. Using a Randomized Controlled Trial (RCT) design, we will test whether augmentation with BBTI will be acceptable to older Veterans and improve treatment response in those whose depression has not improved with antidepressant pharmacotherapy alone and assess for an association between preference and treatment response. Our aims and hypotheses are:

Aim 1: To characterize the depression, insomnia, and relevant clinical and neuropsychiatric characteristics of older Veterans with TRD.

H1a: In Veterans with TRD, Antidepressant History Form (ATHF) scores will have a positive association with Montgomery-Asberg Depression Rating scale (MADRS) scores.

H1b: In Veterans with TRD, MADRS scores will have a positive association with Insomnia Severity Index (ISI) scores.

Aim 2: Perform qualitative interviews in older Veterans to collect information about their views of their depression and insomnia and attitudes and preferences for treatment of both depression and insomnia.

Aim 3: To examine the feasibility of using BBTI to treat Veterans with TRD and insomnia.

H3a: Use of BBTI will be feasible in older adults with TRD as defined by acceptability and retention.

Aim 4: To determine if antidepressant augmentation with BBTI leads to improvement in scores on MADRS and ISI scales in older Veterans receiving BBTI versus those receiving only antidepressant optimization.

H4a: Augmentation with BBTI will improve both PHQ-9 and ISI scores relative treatment with antidepressant alone.

Eligibility Criteria:
* Inclusion Criteria:

  * Age ≥ 60
  * Diagnosis of Major Depressive Disorder (MDD)
  * Diagnosis of Insomnia Disorder
  * Must have failed ≥ 1 antidepressant trial
* Exclusion Criteria:

  * Lifetime/current Bipolar I/II diagnosis
  * Lifetime/current Schizophrenia Spectrum Disorder diagnosis
  * Substance Use Disorder within past 3 months
  * High Suicide Risk that cannot be safely managed
  * Untreated Obstructive Sleep Apnea (OSA)
  * Restless Legs Syndrome
  * Rapid Eye Movement (REM) Sleep Behavior Disorder
  * Active OR untreated Post Traumatic Stress Disorder (PTSD)
Acute Liver Injury in Patients With Pneumonia

Acute liver injury (ALI) is defined as an acute derangement in liver function tests associated with liver-related coagulopathy, in the absence of underlying chronic liver disease.

A subset progress to acute liver failure ,Acute liver failure represent a more severe liver injury results in hepatic encephalopathy

Acute liver injury is associated with a spectrum of haemostatic changes, including thrombocytopenia and reduced platelet function, reduced plasma levels of many coagulation factors such as factor (F)VII and increased levels of FVIII .

Pneumonia is an acute inflammation of the lower respiratory tract. Lower respiratory tract infection is a major cause of mortality worldwide .Pneumonia is most common at the extremes of life.

In adults, pneumonia can be broadly classified, on the basis of chest radiographic appearance, into lobar pneumonia, bronchopneumonia and pneumonia producing an interstitial pattern.

There is lack of data regarding outcome and hospital stay in patients with pneumonia who develop acute liver injury.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with pneumonia that developed Acute Liver Injury
2. Covid 19 pneumonia
3. Patients With acute liver injury only.

Exclusion Criteria:

1. Cancer
2. Immunocompromised patients i.e HIV patients and patients who take immunosuppressive medications.
3. Patients who younger than 18 yrs old
4. pregnancy
Image and Model Based Analysis of Lung Disease

The purpose of this research study is to develop CT scanning and image analysis techniques to help define and measure several key properties of the pulmonary system that cannot be obtained by other tests or exams.

Specifically, the investigators are interested in understanding the difference between the normal aging process and the events that lead to emphysema. Additionally, the investigators are interested in understanding the earliest signs (lung inflammation) of the disease process leading to three lung diseases, which include emphysema, fibrosis and sarcoidosis; all of which are described as "inflammatory lung diseases." The investigators will be using the data from this study to help define the normal values for the measured properties as well as deviation from normal values in smokers without defined lung disease and patients with inflammatory lung disease. The investigators believe that the analysis and scanning techniques being developed as part of this research will provide new and previously unavailable information on normal and diseased lungs so that ultimately the investigators can detect specific changes in the lungs due to a disease and measure any improvements in the anatomy and/or function of the pulmonary system after a patient has undergone treatment. This study involves research using X-Ray computed tomography (CT) scanner, which is similar to previous CT scanners but operates much faster and provides finer image detail.

Eligibility Criteria:
Inclusion Criteria:

* Non smokers, age 20-29, 40-49, 60-69, 80-89, cannot have smoked more than 20 cigarettes in their lifetime
* Smokers, age 20-29, 40-49, 60-69, 80-89, currently smoking a minimum of 1 pack (20 cigarettes) per day, normal smokers and mild to moderate Chronic Obstructive Pulmonary Disease (COPD)

Exclusion Criteria:

* Allergies - no allergies to shellfish, eggs, iodine
* Medications - no medications (except for birth control) for in the 'normal' category
* No asthma - as self reported
* BMI (Body Mass Index) - must not exceed 32 or 100kg of weight
* No other radiology studies in the last 12 months
* No metal in lung field - no metal from larynx to stomach
* No known heart disease
* No known kidney disease or diabetes
* Must not be pregnant - subjects of childbearing potential with be given a urine pregnancy test
Clinical Trial of Experienced Chinese Herbal Formulas on Different Types of Precocious Puberty

Due to various complex factors, the incidence of precocious puberty is increasing rapidly. It severely threatens physical and mental health of children. It's urgent to explore effective ways to control the disease.

In the research, 138 precocious puberty children are randomly divided into the Ziyinxiehuo granules group (69 cases) and Zishenqinggan granules group(69 cases). Patients in Ziyinxiehuo granules group are treated with a series of experienced chinese herbal formulas, whereas the Zishenqinggan granules group received with different series of experienced chinese herbal formulas.

Eligibility Criteria:
1. In the partial precocious puberty children：

   Inclusion Criteria:
   * Girls are diagnosed as simple early breast development, and their age of onset is less than 8 years
   * Tanner stages of breast in female patients are Tanner II and Tanner III, Diameter of mammary nucleus is less than 3cm；
   * B-type ultrasonography: the size and volume of uterus and follicle is in the normal range at the same age；
   * bone age: the bone age in the patients are the same with their actual age.

   Exclusion Criteria:
   * the bone age is advanced by more than 1 standard deviations for chronological age
   * pseudo sexual precocity, including gonadal tumor,adrenal disease,exogenous intake induced with hormone drugs or food and multiple bone fiber structure dysplasia of precocious puberty (McCune Albright syndrome)
   * heterosexual precocious puberty
2. In the mild true precocious puberty children：

Inclusion Criteria:

* Girls are diagnosed as Idiopathic central precocious puberty，and their age of onset ≤8 years
* Tanner stages of brest in female patients ≤ Tanner III stage，diameter of mammillary nucleus \< 3cm
* B-type ultrasonography: the volume of uterus≥1\~3ml，the diameter of follicle≥4mm;or the length of uterus ≥3.4-4cm
* bone age: compared the actual age ,the bone age is no more than 1 year and the bone age \<10 years old;
* in master single test: LH \>3 IU/L
* GnRH stimulation test: LH/FSH\>0.6, the Peak LH 3.5\~5.0 IU/L, the Peak LH 3.5\~5.0 IU/L.

Exclusion Criteria:

* The central nervous system organic diseases caused sexual precocity
* congenital thyroid function reduce disease with precocious puberty, congenital adrenal hyperplasia, adrenal tumor
* ovarian or testicular neoplasms,
* McCune Albright syndrome (precocious puberty with polyostotic fibrous dysplasia and skin pigment abnormalities, pigmentation)
* there is a family history of diseases such as tumor, leukemia, diabetes, systemic lupus erythematosus, etc
* precocious puberty and partial precocious puberty
Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience

The goal of this study is to evaluate the Salah Azaïz Cancer Institute male breast cancer patients population over a period of 14 years.

Goal of the retrospective part: to gather clinicopathologic data and follow-up outcomes of male breast cancer patients diagnosed and/or treated at Salah Azaïz Cancer Institute from 2004 to 2013.

Goal of the prospective part: to create a registry of male patients with breast cancer for a period of 48 months (from 2014 to 2017).


Eligibility Criteria:
Inclusion Criteria:

Histological diagnosis of male breast cancer
Ultrasound Biomicroscopy Study Of Accommodative State In Smartphone Abusers

Detection if there is association between spasm of accommodation and smart phone abuse by ultrasound biomicroscopy on anterior segment of the eye


Eligibility Criteria:
Inclusion Criteria:

1. Age 18 - 35 year.
2. Smart phone excessive use.
3. Emmetrope and myope patients.

Exclusion Criteria:

1. Hypermetrope patients.
2. Any form of tropia.
3. Anterior segment diseases either congenital or acquired.
4. Previous intraocular surgeries.
5. Presbyopic subjects.
6. Drugs induced spasm of accommodation: psychiatric drugs, pilocarpine, physostigmine, echothiophate, prostigmine, isoflurophate, muscarine, digitalis overdose and with sulphonamides
7. CNS diseases : Neurosyphilis, Raeder paratrigeminal neuralgia syndrome, cyclic oculomotor palsy, pineal tumor, Chiari malformation, pituitary tumor, metabolic encephalopathy,
Pharmacists and Pharmacy Technicians to Improve Admission Medication History Accuracy

We tested two interventions to improve the accuracy of medication histories obtained at hospital admission. The interventions target elderly and chronically ill patients prone to erroneous medication histories and resultant medication errors. For targeted patients, we tested the effect of using pharmacists and pharmacy technicians to obtain an initial medication history. This was studied using a randomized controlled trial of usual care (which involves nurses and physicians) vs usual care + pharmacists vs usual care + pharmacy technicians to obtain an admission medication history.

The overarching hypothesis was that by leveraging pharmacists and pharmacy technicians we can minimize admission medication history errors and related downstream events.

Importance: Admission medication history (AMH) errors frequently cause medication order errors and patient harm.

Objective: To quantify AMH error reduction achieved when pharmacy staff obtain AMHs before admission medication orders (AMO) are placed.

Design: Three-arm randomized clinical trial. Setting: Large hospital with community and trainee physicians. Population: 306 enrolled patients with complex medical histories. Interventions: In one intervention arm, pharmacists, and in the second intervention arm, pharmacy technicians obtained initial AMHs prior to admission. They obtained and reconciled medication information from multiple sources. All arms, including the control arm, received usual AMH care. This included common process variation occurring in: accuracy of pre-existing medication histories; nurses' ability to obtain AMHs at hospital admission; and admitting physicians' efforts to verify and order from prior AMHs.

Main Outcomes and Measures: The primary outcome was severity-weighted mean AMH error score. To detect AMH errors, all patients received reference standard AMHs, which were compared with intervention and control group AMHs. AMH errors and resultant AMO errors were independently identified and rated by ≥2 investigators as significant, serious or life-threatening. Each error was assigned 1, 4 or 9 points, respectively, to calculate severity-weighted AMH and AMO error scores for each patient.

Eligibility Criteria:
Inclusion criteria:

* Accessed via EHR, were: \>=10 chronic prescription medications
* History of acute myocardial infarction or congestive heart failure
* Admission from skilled nursing facility
* History of transplant, or active anticoagulant, insulin, or narrow therapeutic index medications.

Exclusion criteria:(supersedes inclusion criteria)

* Admitted to pediatric, trauma or transplant services with pharmacists
Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model

There is a need for safe, highly infectious Norovirus inocula for use in Norovirus vaccine-challenge studies to assess the efficacy of Norovirus vaccines and examine the immune response among vaccinated and unvaccinated subjects. The purpose of this study is to generate the infection and illness rate and immune response data necessary for the conduct of future investigation of Norovirus vaccine studies.


Eligibility Criteria:
Inclusion Criteria:

* General good health, without significant medical illness, based on medical history, physical examination, vital signs, and clinical laboratories (CBC, chemistry, and urinalysis) as determined by the investigator in consultation with the research monitor and sponsor
* Available for all planned visits and to spend at least 5 days in confinement
* Confirmed blood type (A or O)
* Demonstrated to be H type-1 antigen secretor positive (by saliva test)
* Body mass index between 17 and 30 at screening
* Female subjects must have a negative pregnancy test and either use contraceptives or be sterile
* Available to return for follow-up visits following discharge from the inpatient unit and deliver stool specimens to the investigator promptly

Exclusion Criteria:

* Presence of significant medical condition
* Donation or use of blood or blood products within 4 weeks prior to challenge
* Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic
* Abnormal stool pattern
* Any gastroenteritis within the past 2 weeks
* Occupational hazards, including having daily contact with children under the age of 5, women known to be pregnant, employment in the food service industry, health care workers, etc.